IMVT Immunovant, Inc.
USHealthcareAs of 2026-07-10 16:00
Why IMVT matters now
Immunovant, Inc. (IMVT) is a US stock in Healthcare. The latest InvestLog snapshot shows $39.71 with -3.36% on the session and $8.15B in market capitalization; recent performance reads 1-month +34.42% and YTD +39.02%.
The latest financial table shown here is Q4 2026, with revenue of $0.00, net income of $-147.9M, and EPS of $-0.73. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -5.6%.
The latest indexable market news headline is "Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $45.00; recent insider activity includes Pande Atul filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
8.44
P/S
0.00
EV/EBITDA
-12.58
DCF Value
$4.93
FCF Yield
-5.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-68.2%
ROA
-52.8%
ROIC
-62.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2026 | $0.00 | $-147.9M | $-0.73 |
| FY 2026 | $0.00 | $-505.6M | $-2.77 |
| Q3 2026 | $0.00 | $-110.6M | $-0.61 |
| Q2 2026 | $0.00 | $-126.5M | $-0.73 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$45.00
Target (Median)
$45.00
Target Range
$40.00 - $50.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.79
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.